About the event

What if there’s a blood shortage in the operating room?

Losing your own blood and getting it right back? In many surgeries, that’s exactly what’s possible. With cancer surgeries, it gets more complicated. Tumor cells may still be present in the patient’s own blood, and these should not be allowed to re-enter the bloodstream. Each year, approximately 900,000 people require a blood transfusion in connection with cancer surgery.  

The supply of donor blood is becoming an increasing obstacle. Blood units are in short supply; their procurement is complex, and they are indispensable, especially for major surgeries. 

Dr. Franzpeter Bracht has been addressing this challenge for several years. As the founder of Lindis Blood Care, he is advancing an approach that allows tumor cells to be specifically removed from the patient’s blood during intraoperative blood processing in the operating room. In this expert discussion, he and Dr. Stefan Eschbach—a cell biologist with a Ph.D. and co-investor—will provide insights into the technology’s development and demonstrate how this approach could change the use of autologous blood in tumor surgeries in the future. 

Here’s what to expect

• Exclusive insights into a groundbreaking MedTech and biotech innovation 

• The vision and minds behind Lindis Blood Care

• Live discussion with experienced industry experts

Register now

Join a live discussion with Dr. Franzpeter Bracht and Dr. Stefan Eschbach about the future of innovative solutions in medicine and the opportunities for successful biotech and medtech companies. 

Speaker:

Dr. Franzpeter Bracht is the founder and CEO of Lindis Blood Care and has more than 20 years of experience in the pharmaceutical and biotech industries. As a pharmacologist with a Ph.D., he combines scientific expertise with many years of experience in strategy, financing, business development, and clinical development.

Dr. Stefan Eschbach holds a Ph.D. in cell biology and has over 30 years of experience in the medtech and diagnostics industries; he is also a co-investor at Lindis Blood Care. In senior leadership roles, he has been responsible for, among other things, international operations in product development, sales, and business development. He supports life sciences companies as a consultant and investor.